Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas

Sugaya, Makoto

doi:10.3390/ijms222011079

Cited by 6 publications

(5 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because there is no clear consensus on the optimal treatment algorithm, 2 , 3 , 4 , 5 , 6 , 7 individual treatment pathways are highly variable among centers. 10 , 11 To date, there is only 1 randomized clinical trial specifically for relapsed or refractory SS or advanced MF, the MAVORIC study 12 compared mogamulizumab with vorinostat, and in a recently published post hoc analysis, a clear benefit in time-to-next-treatment (TTNT) was observed for patients with B2 blood involvement receiving mogamulizumab (median TTNT, 13.1 vs 3.5 months; P < .0001). 13 However, beyond this, there is a paucity of prospective comparative data examining treatment efficacy for patients with SS.…”

Section: Introductionmentioning

confidence: 99%

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Campbell,

Dobos,

Haider

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study, from three quaternary centers, examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration given to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9 months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies), and classified into 17 treatment groups. First-line, the most common treatments were extracorporeal photopheresis (ECP)-containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4 months). First-line, combination therapies had longer median TTNT than monotherapies: 10.0 vs 5.0 months (p=0.004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2 months for midline (2nd-4th line) and late line (>4th line), respectively (p<0.001). First-line, ECP-containing treatments were associated with longer median TTNT compared to non ECP-containing treatments: 9.0 vs 4.9 months (p=0.007). For both ECP-monotherapy and ECP-containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for patients with SS, and favor early inclusion of ECP in the treatment algorithm for those who can access it.

show abstract

Section: Introductionmentioning

confidence: 99%

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Campbell,

Dobos,

Haider

et al. 2023

Blood Advances

View full text Add to dashboard Cite

show abstract

“…Mogamulizumab has been approved for CCR4+ ATL and for peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL). Sugaya et al enrolled seven patients with MF, and their overall response (ORR) was 28.6% with no complete response (CR) [ 8 ]. Duvic et al conducted a phase ½ study in 41 pre-treated patients with CTCL.…”

Section: Discussionmentioning

confidence: 99%

“…Common side effects were fever, pruritus, nausea, skin eruptions, infusion reactions, and lymphopenia. In 2018, Mogamulizumab has been approved for the treatment of patients with CTCL who have received at least one prior systemic therapy by the FDA and the European Medicines Agency [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background: With the high mortality rate of malignant tumors, there is a need to find novel theranostic approaches to provide an early diagnosis and targeted therapy. The chemokine receptor 4 (CCR4) is highly expressed in various tumors and plays an important role in tumor pathogenesis. This systematic review aims to provide a complete overview on clinical and preclinical applications of the CCR4 receptor as a target for theranostics, using a systematic approach to classify and assemble published studies performed on humans and animals, sorted by field of application and specific tumor. Methods: A systematic literature search of articles suiting the inclusion criteria was conducted on Pubmed, Scopus, Central, and Web of Science databases, including papers published from January 2006 to November 2022. Eligible studies had to be performed on humans and/or in vivo/in vitro studying CCR4 expression in tumors. The methodological quality was assessed through the Critical Appraisal Skills Programme (CASP) assessing only the studies performed on humans. Results: A total of 17 articles were screened. The articles were assessed for eligibility with the exclusion of 4 articles. Ultimately, 13 articles were selected for the qualitative analysis, and six articles were selected for the critical appraisal skills program. Conclusions: The development of new radionuclides and radiopharmaceuticals targeting CCR4 show promising results in the theranostics of CCR4 sensible tumors. Although to widen its use in clinical practice, further translation of preclinical to clinical data is needed.

show abstract

“…STAT3, STAT5 and miR-155 have been previously associated with CTCL pathogenesis ( 14 ). Cobomarsen, an inhibitor of miR-155 expression, is thought to be one of the promising novel therapies in CTCL, currently undergoing phase first-in-human clinical studies ( 26 ). The constant responses of both malignant and benign lymphocytes to the S. aureus inflammation may contribute to carcinogenesis, which would explain why transient, aggressive antibiotic therapy may slow the tumour progression in some cases ( 22 , 27 ).…”

Section: Discussionmentioning

confidence: 99%

Interleukin-17 Genes Polymorphisms are Significantly Associated with Cutaneous T-cell Lymphoma Susceptibility

Kołkowski¹,

Gleń²,

Olszewska³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

Tumour microenvironment has an important effect on the progression of cutaneous T-cell lymphomas. Using PCR with sequence-specific primers, this study analysed single-nucleotide polymorphisms in the interleukin-17 genes of 150 patients with cutaneous T-cell lymphoma. GG homozygote rs8193036 A/G of interleukin-17A gene occurred less commonly in the cutaneous T-cell lymphoma group; however, patients with this single-nucleotide polymorphism experience significantly intense pruritus. Conversely, the rs2397084 AG heterozygote of interleukin-17F is more common in the lymphoma population. In addition, there were significant differences in the frequencies of interleukin-17 genotypes when comparing early (Ia to IIa) and advanced stages (IIb, III and IV) of this neoplasms. A similar result has been shown in comparison between Sézary syndrome and mycosis fungoides. The current data may serve as a possible explanation for the increased bacterial infection rates in the course of cutaneous T-cell lymphoma, especially caused by Staphylococcus aureus. In summary, specific single-nucleotide polymorphisms occur with different frequencies between cutaneous T-cell lymphoma and healthy patients. Moreover, genetic predisposition of several interleukin-17 single-nucleotide polymorphisms may be a factor causing impaired immune defence in cutaneous lymphomas.

show abstract

Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas

Cited by 6 publications

References 63 publications

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review

Interleukin-17 Genes Polymorphisms are Significantly Associated with Cutaneous T-cell Lymphoma Susceptibility

Contact Info

Product

Resources

About